Highlights Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Market Closed - Nyse Other stock markets 04:00:01 2024-04-29 pm EDT			5-day change	1st Jan Change
8.88 ^USD	+1.95%		+5.09%	+10.72%

Apr. 25	Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	MT
Apr. 25	Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
Bausch wins US appeal to block Alvogen generic of diarrhea drug	Apr. 11	RE
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	Apr. 11	CI
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	Apr. 08	MT
RBC Raises Bausch Health Target to US$12, Maintains Sector Perform, on Upcoming Xifaxan Litigation Ruling	Apr. 05	MT
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for Uceris Aerosol Foam	Apr. 03	MT
Bausch Health Brief: Bausch Health, Canada Inc. Announcing First Public Drug Plan Listings for UCERIS Aerosol Foam	Apr. 03	MT
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults	Apr. 03	CI
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor	Mar. 06	MT
Bausch Health Brief: Salix Pharmaceuticals Announcing a Phase 2 Investigator-Initiated Study of RELISTOR (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma	Mar. 06	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma	Mar. 06	CI
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell	Feb. 22	MT
Bausch Health Reports Q4 2023 Adjusted Earnings of US$406 Million; Revenue of US$2.4 Billion	Feb. 22	MT
Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2024	Feb. 22	CI
Bausch Health Brief: Adjusted EBITDA Attributable of US$869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year	Feb. 22	MT
Bausch Health Brief: Fourth-Quarter revenues of US$2.41 billion, up 10% on a Reported basis and up 4% on an Organic Basis	Feb. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Highlights

Filters